SOURCE: World Street Fundamentals

November 07, 2011 09:00 ET

A Turn in Tide, Europe's New Deal - Research Report on Achillion Pharmaceuticals, Inc. and Idenix Pharmaceuticals, Inc.

HONG KONG--(Marketwire - Nov 7, 2011) - Today, released its industry report highlighting Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN) and Idenix Pharmaceuticals, Inc. (NASDAQ: IDIX). Full fundamental and technical analysis is available at

Markets are starting to step in the right direction, with the European Financial Stability Facility (EFSF) increasing from $600 billion to $1.4 trillion, a significant move to strengthen the safety net in place for Europe's most troubled countries.

It is likely China and the IMF will contribute to the bailout fund, with Greece alone receiving $180 billion in fresh aid. The remainder of Greece's obligations were halved in the process, with private bondholders of Greek debt settling at 50% -- allowing banks to recapitalize at a healthy 9% reserve and bring Greece's debt burden down to 120% of GDP by 2020.

An important consideration is political commitment to this road map and probability of ongoing support for European Central Bank (ECB)'s recent deal. Currently the global community appears to be on point with ECB's initiative, an outlook that should be sufficient to support markets around current levels.

World Street Fundamentals has highlighted Achillion Pharmaceuticals, Inc. for its current position within the healthcare industry. Achillion Pharmaceuticals, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of treatments for infectious diseases. The entire report on Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN) is available here:

World Street has featured Idenix Pharmaceuticals, Inc. for its development within the healthcare industry. Idenix Pharmaceuticals, Inc. (Idenix) is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases with operations in the United States and Europe. The Company's research and development focus is on the treatment of hepatitis C virus (HCV). The entire report on Idenix Pharmaceuticals, Inc. (NASDAQ: IDIX) is available here:

About World Street
World Street Fundamentals is an online portal for professionals, investors and new-comers to the markets to find in depth comprehensive research and research tools to help guide you through the ever changing financial markets.

Contact Information